ReviewJCO oncology practice2020
Impact of Pharmacy Benefit Managers on Oncology Practices and Patients.
Review in JCO oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 21 citations in OpenAlex.
- Longitudinal Associations Between Financial Toxicity and Health-Related Quality of Life for Patients With Cancer.JCO oncology practice · 2026Article
- Patient factors and costs associated with prophylactic neurokinin-1 receptor antagonist use among women with invasive breast cancer.Journal of managed care & specialty pharmacy · 2026Article
- System-Level Transformations to Increase Patient Participation in Clinical Trials.JCO oncology practice · 2025Article
- Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.Blood cancer journal · 2024Review
- Article
- The impact of pharmacy benefit managers on community pharmacy: A scoping review.Exploratory research in clinical and social pharmacy · 2023Article
- A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.International journal of health services : planning, administration, evaluation · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Pharmacy benefit managers (PBMs) are thoroughly integrated into the drug supply chain as administrators of prescription drug benefits for private insurers, self-insuring business, and government health plans. As the role of PBMs has expanded, their opaque business practices and impact on drug prices have come under increasing scrutiny. PBMs are particularly influential in oncology care because prescription drugs play a major role in the treatment of most cancers and an increasing number of patients with cancer are treated with oral oncology agents managed by PBMs. There is concern that some PBM practices may threaten access to high-quality cancer care and may increase the financial and administrative burden on patients and practices. In this article, we review the role of PBMs in prescription drug coverage and reimbursement, discuss the impact of PBMs on oncology care, and present data from the 2018 ASCO Practice Survey assessing the knowledge and attitude of oncology practices toward PBMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.